Continuous Monitoring of Vital Signs and Laboratory Values to Reduce Side Effects in Cancer Patients Receiving Chemotherapy with Moderate or High Risk of Febrile Neutropenia or Immunotherapy, PR-DOC Trial
This clinical trial studies whether continuous monitoring of vital signs and laboratory (lab) values can be used to reduce side effects in cancer patients receiving chemotherapy with a moderate or high risk of febrile neutropenia or immunotherapy. Cancer treatment often includes medicine that kills tumor cells (chemotherapy) or treatment that helps the immune system fight cancer (immunotherapy). Undergoing cancer treatment comes with various risks and side effects, such as febrile neutropenia. Febrile neutropenia is a condition marked by fever and a lower-than-normal number of neutrophils in the blood. A neutrophil is a type of white blood cell that helps fight infection. Having too few neutrophils increases the risk of infection. Current monitoring of side effects depends heavily on patient reporting, which can lead to a delay in necessary treatments. An Alio Smartpatch™ is a wireless remote monitoring system. The patient wears the Alio Smartpatch and the device measures vital signs and basic lab values. The data collected from the device is remotely monitored at all times by clinical staff at a company known as Quantify Remote Care (QRC). If a result looks like a patient could be having a side effect, they are contacted immediately by the QRC team. The QRC team serves as an extension of the patient's cancer clinical team, and they are able to relay any significant issues back to them. This may help identify and treat potential side effects before they get too bad, which may reduce side effects.